Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ImClone Systems, Inc.

http://www.imclone.com

Latest From ImClone Systems, Inc.

Biopharma Industry Sharply Divided Over Supreme Court Antibody Patent Brawl

Big biologic makers line up on opposite sides of dispute between Amgen and Sanofi over whether Amgen’s Repatha patents cover analogous antibodies with the same functional characteristics.

Biologics Intellectual Property

Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances

Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.

Scrip Asks Research & Development

Redx Joins Forces With Jounce To Form $425m Cancer And Fibrosis Company

After a rollercoaster of a journey to date, UK firm Redx unveiled plans to merge with US biotech Jounce in a deal that would create a $425m transatlantic company with a robust cash runway through to 2025.

M & A Companies

Biogen's Return Of Rights To InnoCare Deals Blow To Made In China Innovation

Biogen’s return of rights to the BTK inhibitor orelabrutinib to originator InnoCare signals an ongoing tough reality for Chinese biotechs with go-global ambitions.

Deals Research & Development
See All

Company Information

UsernamePublicRestriction

Register